NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Kadmon Holdings Inc (F: KDF)

 
KDF Technical Analysis
5
As on 8th Nov 2021 KDF STOCK Price closed @ 8.09 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.47 & Strong Buy for SHORT-TERM with Stoploss of 3.22 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

KDFSTOCK Price

Open 8.03 Change Price %
High 8.09 1 Day -0.01 -0.12
Low 8.03 1 Week 0.10 1.25
Close 8.09 1 Month 0.62 8.30
Volume 200 1 Year 4.75 142.22
52 Week High 8.16 | 52 Week Low 2.75
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
30T 1000000.00 3759298.50%
 
F Germany Top Losers Stocks
3HB 0.00 -100.00%
3HB 0.00 -100.00%
3HB 0.00 -100.00%
UFX 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
 
 
KDF
Daily Charts
KDF
Intraday Charts
Whats New @
Bazaartrend
KDF
Free Analysis
 
KDF Important Levels Intraday
RESISTANCE8.21
RESISTANCE8.17
RESISTANCE8.15
RESISTANCE8.12
SUPPORT8.06
SUPPORT8.03
SUPPORT8.01
SUPPORT7.97
 
KDF Forecast December 2025
4th UP Forecast10.02
3rd UP Forecast9.4
2nd UP Forecast9.02
1st UP Forecast8.64
1st DOWN Forecast7.55
2nd DOWN Forecast7.16
3rd DOWN Forecast6.78
4th DOWN Forecast6.16
 
KDF Weekly Forecast
4th UP Forecast9.27
3rd UP Forecast8.89
2nd UP Forecast8.66
1st UP Forecast8.42
1st DOWN Forecast7.76
2nd DOWN Forecast7.52
3rd DOWN Forecast7.29
4th DOWN Forecast6.91
 
KDF Forecast2025
4th UP Forecast18.61
3rd UP Forecast15.24
2nd UP Forecast13.15
1st UP Forecast11.07
1st DOWN Forecast5.11
2nd DOWN Forecast3.03
3rd DOWN Forecast0.94
4th DOWN Forecast-2.43
 
 
KDF Other Details
Segment EQ
Market Capital 1439283584.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
KDF Address
KDF
 
KDF Latest News
 
Your Comments and Response on Kadmon Holdings Inc
 
KDF Business Profile
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York. Address: 450 East 29th Street, New York, NY, United States, 10016
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service